Table 1: Characteristics of included trials

Table 1: Characteristics of included trials									
	First author	Country	Number of patients(n)	Cancer	Interventi Drugs or non-drugs	Dosage	Administration	Placebo	Outpatients/ Inpatients
8]	Bergqvist(2002)[1	France	332	Abdominal or pelvic cancer	enoxaparin	40 mg	Subcutaneous enoxaparin once daily for 19 to 21 days	placebo	inpatients
	Cerrato(1978)[19]	Italy	100	Brain cancer	Calcium heparin	5,000U	Give calcium heparin subcutaneously 2 hours before surgery and every 8 hours thereafter for at least 7 days.	thrombo prophyla	inpatients
	Daniel(1983)[20]	USA	185	Gynecologic tumor	Sodium heparin	5,000 U	Subcutaneously 2 hours preoperatively and every 12 hours postoperatively for the first 7 postoperative days.	placebo	Inpatients
	Daniel(1984)[21]	USA	194	Gynecologic tumor	Perioperative External Pneumatic Calf Compression	NA	Calf compression continued until discharge from the recovery room or through the first 24 hr postoperatively	thrombo prophyla	inpatients
	Gondret(1995)[22]	France	40	Head and neck cancer	enoxaparin	0.2 ml	once a day, for 8 days after the operation	placebo	inpatients
	Kakkar(2010)[23]	Italy	625	Abdominal or pelvic cancer	bemiparin	0.2 ml	Subcutaneous injections of bemiparin sodium for 20 ± 2 additional days.	placebo	inpatients
	Negm(2017)[24]	Egypt	40	Hepatocellular carcinoma	LMWH enoxheparin	1 IU/kg	Twice daily for 2 weeks from the first day of TACE	no thrombo prophyla xis	inpatients
	Perry(2010)[11]	Canada	186	Malignant glioma	LMWH dalteparin	5,000 IU	Subcutaneously once daily	placebo	inpatients
	Shukla(2008)[25]	India	99	Colorectal cancer	dalteparin sodium	2,500 IU	Subcutaneously about 2 hours before surgery, followed by 2500 IU daily subcutaneously in the morning the prophylaxis was continued until day 6±1.	thrombo prophyla	inpatients
	Srikuea(2017)[26]	Thailand	108	Gynecologic and urological cancer	eoxaparin	0.4 ml	Started after drain removal until 4 weeks postoperatively	no thrombo prophyla xis	outpatients
	Turpie(1977)[27]	Canada	128	Brain cancer	Pneumatic compression	NA	Intermittent calf compression was started during the immediate postoperative period and was continued for a maximum of 5 days	no thrombo prophyla xis	inpatients

8]	Abdelkefi(2004)[2	Tunisia	108	Haematological malignancies	Unfractionat ed heparin	100IU/kg /d	continuous infusion of 100 IU/kg/daily, with a maximal dose of UFH 10000 IU daily	thrombo prophyla	inpatients
	Agnelli(2009)[29]	Italy	1150	metastatic or locally advanced solid cancer	Nadroparin	3800 IU	receive subcutaneous injections of nadroparin once a day. Study treatment was started on the same day as chemotherapy, and was given for the duration of chemotherapy or up to a maximum of 120 days (±10 days).	placebo	ambulatory patients
	Agnelli(2012)[30]		3212	cancer of the lung, pancreas, stomach, colon or rectum, bladder, or ovary.		20 mg	20 mg once daily, or placebo until there was a change of chemotherapy regimen	placebo	inpatients
	Bern (1990)[31]	England	87	Colon, Breast, et al	warfarin	1 mg	Warfarin therapy was continued at this dose for 90 days or until there was venogram evidence of thrombosis.	placebo	inpatients
	Boraks(1998)[32]	UK	223	Haematological malignancies	Warfarin	1mg/d	From the time of line insertion until removal	no thrombo prophyla xis	inpatients
3]	Doormaal(2011)[3	Italy	498	hormone-refractory prostate cancer, non-small-cell lung cancer [NSCLC] IIIB, and locally advanced pancreatic cancer	nadroparin	50 kg, 3,800 IU twice daily; 50- 70 kg, 11,400 IU once daily; 70 kg, 15,200 IU once daily	daily; 70 kg, 7,600 IU		inpatients
	Ek(2017)[34]	Canada, Sweden , Denmark	377	SCLC	enoxaparin	1 mg/kg	The study drug was started on day 1 of chemotherapy and continued until the 21st day of the last chemotherapy cycle.	thrombo prophyla	inpatients
	Haas(2012)[35]	Germany, Czech Republic, Ukraine, Romania, and Belarus.	898	Metastatic Breast Cancer or Stage III/IV Lung Cancer	certoparin	3000 IU	once daily for 6 months	placebo	inpatients

	Heaton(2002)[36]	New Zealand	88	Haematological malignancies	Warfarin	NA	receive either a daily minidose of warfarin	no anticoag ulation	inpatients
	Kakkar(2004)[37]	UK	385	Advanced Cancer	Dalteparin	5,000 IU	receive once-daily subcutaneous injections of dalteparin	placebo	inpatients
]	Karthaus(2006)[38	Germany	439	Cancer	Dalteparin	5,000 IU		placebo	inpatients
	Levine(1994)[39]	Canada	311	breast cancer	very-low- dose warfarin	1 mg	daily for 6 weeks while placebo patients took an identical inert tablet daily	Placebo	inpatients?
	Levine(2012)[40]	Canada, USA	125	advanced or metastatic lung, breast, gastrointestinal, bladder, ovarian or prostate cancers, cancer of unknown origin, myeloma or selected lymphomas	Apixaban	5 mg, 10 mg or 20 mg	once daily of apixaban	placebo	inpatients
M	faraveyas(2010)[43]	UK	123	advanced or metastatic pancreatic cancer	Gemcitabine	1000 mg/m ²	gemcitabine 1000 mg/m2 (Burris schedule) for 3 months stratified by extent of disease (LA vs. M), and KPS (90–100 vs. 80–60).	thrombo prophyla	inpatients
M	faraveyas(2012)[42]	UK	121	pancreatic adenocarcinoma	Dalteparin	200 IU/kg		Gemcita bine was given on a conventi onal schedule as describe d by Burris et al.11 Respons e assessme nt was planned for week 12.	inpatients
[4	Monreal (1996)	Spain	29	cancer	low molecular weight heparin	2500IU sc	once a daily, starting 2h before insertion of the catheter	no thrombo prophyla xis	inpatients

Niers(2007)[44]	Netherla nds	113	Hematologic malignancies	LMWH anti- FXa	2850 U	started 2 h before insertion of the CVC, and was continued for 3 weeks or until the day of CVC removal	placebo	inpatients
Pelzer(2015)[45]	Germany	312	Advanced pancreatic cancer	enoxaparin	1 mg/kg	once daily subcutaneously	observati on group	•
Young(2009)[46]	UK	812	cancer	Warfarin	1 mg/d	From 3 days before CVC insertion. Patients took oral warfarin every day until thrombosis occurred or the catheter had to be removed for any reason and patients were able to temporarily discontinue treatment in the event of thrombocytopenia	no thrombo	N/A
Khorana(2017)[47]	USA	98	Malignancy cancer	Dalteparin	500units	5000 units subcutaneously daily or observation for a period of 12weeks	observati on group	inpatients
Verso(2005)[48]	Italy	385	cancer	Enoxaparin	40 mg	the dose of 40 mg once daily	Placebo	inpatients
Lecumberri(2013)[49]	Spain	38	cancer	Bemiparin	3500IU	The same first line therapy + bemiparin 3,500 IU subcutaneous daily for 26 weeks (or until disease progression, whatever appeared first), starting the first day of chemotherapy	Chemora diothera py	inpatients

N/A: not available.